Mitchell MD - Alpine Immune Executive CEO
ALPNDelisted Stock | USD 12.37 0.23 1.83% |
CEO
Mitchell MD is Executive CEO of Alpine Immune Sciences
Age | 56 |
Phone | 206 788 4545 |
Web | https://www.alpineimmunesciences.com |
Alpine Immune Management Efficiency
The company has return on total asset (ROA) of (0.101) % which means that it has lost $0.101 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1467) %, meaning that it created substantial loss on money invested by shareholders. Alpine Immune's management efficiency ratios could be used to measure how well Alpine Immune manages its routine affairs as well as how well it operates its assets and liabilities.Alpine Immune Sciences currently holds 9.91 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Alpine Immune Sciences has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alpine Immune's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Found 8 records | CEO Age | ||
Jon Congleton | Mineralys Therapeutics, Common | 61 | |
Amy MBA | Terns Pharmaceuticals | 54 | |
Fred JD | IGM Biosciences | 71 | |
Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
Jeremy MBA | Day One Biopharmaceuticals | 53 | |
Daniel MBA | Acumen Pharmaceuticals | 54 | |
Markus MD | Monte Rosa Therapeutics | 53 | |
Faraz MBA | Tenaya Therapeutics | 51 |
Management Performance
Return On Equity | -0.15 | |||
Return On Asset | -0.1 |
Alpine Immune Sciences Leadership Team
Elected by the shareholders, the Alpine Immune's board of directors comprises two types of representatives: Alpine Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alpine. The board's role is to monitor Alpine Immune's management team and ensure that shareholders' interests are well served. Alpine Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alpine Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
Temre Johnson, Head Communications | ||
Remy Durand, Chief Officer | ||
Andrew MD, Chief Officer | ||
Paul Rickey, CFO, Senior Vice President Secretary | ||
Stanford MD, President Development | ||
Wayne Gombotz, Chief Officer | ||
Mitchell MD, Executive CEO | ||
Pamela Holland, VP Research | ||
Wolfgang MD, Chief Officer | ||
Christina Yi, Chief Officer |
Alpine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alpine Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.15 | |||
Return On Asset | -0.1 | |||
Profit Margin | (0.65) % | |||
Operating Margin | (3.23) % | |||
Current Valuation | 4.16 B | |||
Shares Outstanding | 68.6 M | |||
Shares Owned By Insiders | 4.60 % | |||
Shares Owned By Institutions | 99.46 % | |||
Number Of Shares Shorted | 3.89 M | |||
Price To Earning | (32.69) X |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Alpine Stock
If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |